Baillie Gifford & Co
PLX icon

Baillie Gifford & Co’s Protalix BioTherapeutics PLX Stock Holding History

Baillie Gifford & Co’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-636,136
Closed -$3.56M – 200
2016
Q3 		$3.56M Hold
636,136
– – 0.01% 185
2016
Q2 		$4.07M Sell
636,136
-4,474
-0.7% -$35.8K 0.01% 176
2016
Q1 		$5.38M Hold
640,610
– – 0.01% 173
2015
Q4 		$6.53M Sell
640,610
-1,305
-0.2% -$13.3K 0.01% 155
2015
Q3 		$7.58M Sell
641,915
-6,247
-1% -$99.3K 0.01% 156
2015
Q2 		$12.6M Sell
648,162
-2,854
-0.4% -$59.2K 0.02% 135
2015
Q1 		$11.6M Hold
651,016
– – 0.02% 138
2014
Q4 		$12M Hold
651,016
– – 0.02% 135
2014
Q3 		$15.8M Buy
651,016
+10,257
+2% +$296K 0.03% 127
2014
Q2 		$23.4M Buy
640,759
+52,537
+9% +$2.12M 0.05% 119
2014
Q1 		$26.9M Sell
588,222
-4,705
-0.8% -$220K 0.06% 114
2013
Q4 		$23.1M Buy
592,927
+38,092
+7% +$1.6M 0.05% 120
2013
Q3 		$25.1M Buy
554,835
+76,829
+16% +$3.94M 0.06% 109
2013
Q2 		$23.5M Buy
+478,006
New +$25.4M 0.07% 104

Other funds holding PLX

HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AGC
Angelo Gordon & Co New York $1.06B AUM 47.95% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Baillie Gifford & Co's PLX Position: Q4 2016 in Review

Baillie Gifford & Co sold out of Protalix BioTherapeutics (PLX) in Q4 2016, closing a stake of 636,136 shares — an estimated $3.56M sold.

Baillie Gifford & Co first reported a position in PLX in Q2 2013 and held it in 14 quarters. The position peaked at $26.9M in Q1 2014. 33 funds tracked by Wall St. Rank hold PLX as of Q4 2016.

  • Baillie Gifford & Co reported no remaining Protalix BioTherapeutics position as of Q4 2016 after selling out during the quarter.
  • Baillie Gifford & Co sold 636,136 Protalix BioTherapeutics shares in Q4 2016, an estimated $3.56M.
  • Baillie Gifford & Co first reported a position in Protalix BioTherapeutics in Q2 2013 and held it in 14 quarters.
  • Baillie Gifford & Co's Protalix BioTherapeutics position peaked at $26.9M in Q1 2014.
  • 33 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q4 2016.

Based on Baillie Gifford & Co's 13F filing for Q4 2016, filed 14 Feb 2017.